Evidence map›Paper›PMID 28716104›Full record

ArticleParticle and fibre toxicology2017

Evaluating the potential of gold, silver, and silica nanoparticles to saturate mononuclear phagocytic system tissues under repeat dosing conditions.

James L Weaver, Grainne A Tobin, Taylor Ingle, Simona Bancos, David Stevens, Rodney Rouse, Kristina E Howard, David Goodwin, Alan Knapton, Xiaohong Li and 10 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Particle and fibre toxicology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 45 citations in OpenAlex.

  1. Review
  2. Review
  3. Effects of silica nanoparticles with varied physicochemical properties on the survival and functionality of saturated macrophages.Journal of controlled release : official journal of the Controlled Release Society · 2025
    Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Nanocarrier-Based Drug Delivery for Melanoma Therapeutics.International journal of molecular sciences · 2021
    Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 3 institutions in 1 country.

James L WeaverCenter for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, 20993, USA.
Grainne A TobinCenter for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, 20993, USA.
Taylor IngleNational Center for Toxicological Research, Food and Drug Administration, Jefferson, AR, 72079, USA.
Simona BancosCenter for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, 20993, USA.
David StevensCenter for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, 20993, USA.
Rodney RouseCenter for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, 20993, USA.
Kristina E HowardCenter for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, 20993, USA.
David GoodwinCenter for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, 20993, USA.
Alan KnaptonCenter for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, 20993, USA.
Xiaohong LiCenter for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, 20993, USA.
Katherine SheaCenter for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, 20993, USA.
Sharron StewartCenter for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, 20993, USA.
Lin XuCenter for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, 20993, USA.
Peter L GoeringCenter for Devices and Radiological Health, Food and Drug Administration, Silver Spring, MD, 20993, USA.
Qin ZhangCenter for Devices and Radiological Health, Food and Drug Administration, Silver Spring, MD, 20993, USA.
Paul C HowardNational Center for Toxicological Research, Food and Drug Administration, Jefferson, AR, 72079, USA.
Jessie CollinsNational Center for Toxicological Research, Food and Drug Administration, Jefferson, AR, 72079, USA.
Saeed KhanNational Center for Toxicological Research, Food and Drug Administration, Jefferson, AR, 72079, USA.
Kidon SungNational Center for Toxicological Research, Food and Drug Administration, Jefferson, AR, 72079, USA.
Katherine M TynerCenter for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, 20993, USA. Katherine.Tyner@fda.hhs.gov.ORCID 0000-0003-3812-6381
Center for Drug Evaluation and Research · USNational Center for Toxicological Research · USCenter for Devices and Radiological Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAs nanoparticles (NPs) become more prevalent in the pharmaceutical industry, questions have arisen from both industry and regulatory stakeholders about the long term effects of these materials. This study was designed to evaluate whether gold (10 nm), silver (50 nm), or silica (10 nm) nanoparticles administered intravenously to mice for up to 8 weeks at doses known to be sub-toxic (non-toxic at single acute or repeat dosing levels) and clinically relevant could produce significant bioaccumulation in liver and spleen macrophages.

resultsRepeated dosing with gold, silver, and silica nanoparticles did not saturate bioaccumulation in liver or spleen macrophages. While no toxicity was observed with gold and silver nanoparticles throughout the 8 week experiment, some effects including histopathological and serum chemistry changes were observed with silica nanoparticles starting at week 3. No major changes in the splenocyte population were observed during the study for any of the nanoparticles tested.

conclusionsThe clinical impact of these changes is unclear but suggests that the mononuclear phagocytic system is able to handle repeated doses of nanoparticles.

Indexed as

NanoparticlesAnimalsBiomarkersFemaleGoldInjections, IntravenousLiverMacrophagesMetal NanoparticlesMice, Inbred BALB CRisk AssessmentSilicon DioxideSilverSpleenTime FactorsTissue DistributionBiomarkersGoldSilicon DioxideSilverDurable nanoparticlesgold nanoparticlesrepeat dosesilica nanoparticlessilver nanoparticles

Identifiers

PMID28716104
PMCPMC5513057
OpenAlexW2735324979

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.